JP2019517473A - 難治性全身型重症筋無力症の処置のための方法 - Google Patents

難治性全身型重症筋無力症の処置のための方法 Download PDF

Info

Publication number
JP2019517473A
JP2019517473A JP2018562058A JP2018562058A JP2019517473A JP 2019517473 A JP2019517473 A JP 2019517473A JP 2018562058 A JP2018562058 A JP 2018562058A JP 2018562058 A JP2018562058 A JP 2018562058A JP 2019517473 A JP2019517473 A JP 2019517473A
Authority
JP
Japan
Prior art keywords
eculizumab
patient
treatment
weeks
myasthenia gravis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018562058A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019517473A5 (enExample
Inventor
カミール・ベドロシアン
ファニー・オブライエン
ジン・ジン・ワン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alexion Pharmaceuticals Inc
Original Assignee
Alexion Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alexion Pharmaceuticals Inc filed Critical Alexion Pharmaceuticals Inc
Publication of JP2019517473A publication Critical patent/JP2019517473A/ja
Publication of JP2019517473A5 publication Critical patent/JP2019517473A5/ja
Priority to JP2022100008A priority Critical patent/JP2022126773A/ja
Priority to JP2024134758A priority patent/JP2024156984A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/34—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration
    • A61M1/3496—Plasmapheresis; Leucopheresis; Lymphopheresis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2018562058A 2016-05-27 2017-05-15 難治性全身型重症筋無力症の処置のための方法 Pending JP2019517473A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022100008A JP2022126773A (ja) 2016-05-27 2022-06-22 難治性全身型重症筋無力症の処置のための方法
JP2024134758A JP2024156984A (ja) 2016-05-27 2024-08-13 難治性全身型重症筋無力症の処置のための方法

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201662342321P 2016-05-27 2016-05-27
US62/342,321 2016-05-27
US201662346168P 2016-06-06 2016-06-06
US62/346,168 2016-06-06
US201762489240P 2017-04-24 2017-04-24
US62/489,240 2017-04-24
US201762500643P 2017-05-03 2017-05-03
US62/500,643 2017-05-03
PCT/US2017/032767 WO2017205101A1 (en) 2016-05-27 2017-05-15 Methods for treatment of refractory generalized myasthenia gravis

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2022100008A Division JP2022126773A (ja) 2016-05-27 2022-06-22 難治性全身型重症筋無力症の処置のための方法
JP2024134758A Division JP2024156984A (ja) 2016-05-27 2024-08-13 難治性全身型重症筋無力症の処置のための方法

Publications (2)

Publication Number Publication Date
JP2019517473A true JP2019517473A (ja) 2019-06-24
JP2019517473A5 JP2019517473A5 (enExample) 2020-05-14

Family

ID=60412593

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018562058A Pending JP2019517473A (ja) 2016-05-27 2017-05-15 難治性全身型重症筋無力症の処置のための方法
JP2022100008A Pending JP2022126773A (ja) 2016-05-27 2022-06-22 難治性全身型重症筋無力症の処置のための方法
JP2024134758A Pending JP2024156984A (ja) 2016-05-27 2024-08-13 難治性全身型重症筋無力症の処置のための方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022100008A Pending JP2022126773A (ja) 2016-05-27 2022-06-22 難治性全身型重症筋無力症の処置のための方法
JP2024134758A Pending JP2024156984A (ja) 2016-05-27 2024-08-13 難治性全身型重症筋無力症の処置のための方法

Country Status (11)

Country Link
US (3) US20170342139A1 (enExample)
EP (2) EP3909609A1 (enExample)
JP (3) JP2019517473A (enExample)
KR (1) KR20190012199A (enExample)
CN (1) CN109475630A (enExample)
AU (1) AU2017269839A1 (enExample)
BR (1) BR112018073945A2 (enExample)
CA (1) CA3024618A1 (enExample)
MX (1) MX2018014560A (enExample)
RU (1) RU2018141451A (enExample)
WO (1) WO2017205101A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022126773A (ja) * 2016-05-27 2022-08-30 アレクシオン ファーマシューティカルズ インコーポレイテッド 難治性全身型重症筋無力症の処置のための方法

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2017005774A (es) 2014-12-19 2017-07-28 Chugai Pharmaceutical Co Ltd Anticuerpos antimiostatina, polipeptidos que contienen regiones fc variantes, y metodos de uso.
MY191668A (en) 2016-06-14 2022-07-06 Regeneron Pharma Anti-c5 antibodies and uses thereof
JP2021506241A (ja) 2017-12-13 2021-02-22 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 抗ｃ５抗体組み合わせ物およびその使用
JP2022500427A (ja) * 2018-09-17 2022-01-04 国立大学法人京都大学 肝傷害又は肝不全の処置のための抗ｃ５剤の投与
WO2020106724A1 (en) * 2018-11-20 2020-05-28 Alexion Pharmaceuticals, Inc. Methods for treatment of refractory generalized myasthenia gravis in pediatric patients
WO2020168079A1 (en) * 2019-02-14 2020-08-20 Alexion Pharmaceuticals, Inc. Dosage and administration of anti-c5 antibodies for treatment of generalized myasthenia gravis
US20220259305A1 (en) * 2019-08-05 2022-08-18 Alexion Pharmaceuticals, Inc. Methods for treatment of refractory generalized myasthenia gravis with eculizumab

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012508262A (ja) * 2008-11-10 2012-04-05 アレクシオン ファーマシューティカルズ， インコーポレイテッド 補体関連障害を処置するための方法および組成物
WO2015134894A1 (en) * 2014-03-07 2015-09-11 Alexion Pharmaceuticals, Inc. Anti-c5 antibodies having improved pharmacokinetics

Family Cites Families (141)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3710795A (en) 1970-09-29 1973-01-16 Alza Corp Drug-delivery device with stretched, rate-controlling membrane
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
WO1987000201A1 (en) 1985-07-05 1987-01-15 Whitehead Institute For Biomedical Research Epithelial cells expressing foreign genetic material
US4980286A (en) 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
US4863457A (en) 1986-11-24 1989-09-05 Lee David A Drug delivery device
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
EP0633318A1 (en) 1987-09-11 1995-01-11 Whitehead Institute For Biomedical Research Transduced fibroblasts and uses therefor
DE3851153T2 (de) 1987-12-11 1995-01-05 Hughes Howard Med Inst Genetische modifizierung von endothelialen zellen.
EP0400047B1 (en) 1988-02-05 1997-04-23 Whitehead Institute For Biomedical Research Modified hepatocytes and uses therefor
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5164188A (en) 1989-11-22 1992-11-17 Visionex, Inc. Biodegradable ocular implants
JP3418982B2 (ja) 1990-10-31 2003-06-23 ソマティクス セラピー コーポレイション 内皮細胞の遺伝的変性
KR0185215B1 (ko) 1990-11-30 1999-05-01 요시다 쇼오지 서방성 안구삽입용 약제
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
BR9306765A (pt) 1992-07-23 1998-12-08 Minnesota Mining & Mfg Processo para a preparação de uma partícula abrasiva e artigo abrasivo
US6005079A (en) 1992-08-21 1999-12-21 Vrije Universiteit Brussels Immunoglobulins devoid of light chains
EP0656946B2 (en) 1992-08-21 2010-03-31 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
US5885573A (en) 1993-06-01 1999-03-23 Arch Development Corporation Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
IT1265573B1 (it) 1993-09-17 1996-11-22 Zanussi Grandi Impianti Spa Forno di cottura di alimenti con porta perfezionata
US5308341A (en) 1993-09-28 1994-05-03 Becton, Dickinson And Company Method of testing the dose accuracy of a medication delivery device
US5443505A (en) 1993-11-15 1995-08-22 Oculex Pharmaceuticals, Inc. Biocompatible ocular implants
ATE264096T1 (de) 1994-03-07 2004-04-15 Nektar Therapeutics Verfahren und mittel zur verabreichung von insulin über die lunge
US6074642A (en) 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
US6019968A (en) 1995-04-14 2000-02-01 Inhale Therapeutic Systems, Inc. Dispersible antibody compositions and methods for their preparation and use
CA2229043C (en) 1995-08-18 2016-06-07 Morphosys Gesellschaft Fur Proteinoptimierung Mbh Protein/(poly)peptide libraries
US5773019A (en) 1995-09-27 1998-06-30 The University Of Kentucky Research Foundation Implantable controlled release device to deliver drugs directly to an internal portion of the body
WO1997034631A1 (en) 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
AU3117697A (en) 1996-05-06 1997-11-26 Uab Research Foundation, The Radiolabeled fusion toxins for cancer therapy
US6146361A (en) 1996-09-26 2000-11-14 Becton Dickinson And Company Medication delivery pen having a 31 gauge needle
WO1998023289A1 (en) 1996-11-27 1998-06-04 The General Hospital Corporation MODULATION OF IgG BINDING TO FcRn
GB9626960D0 (en) 1996-12-27 1997-02-12 Glaxo Group Ltd Valve for aerosol container
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
WO1998047531A2 (en) 1997-04-21 1998-10-29 Arch Development Corporation Fc receptor non-binding anti-cd3 monoclonal antibodies deliver a partial tcr signal and induce clonal anergy
US6096872A (en) 1997-10-14 2000-08-01 Ortho Diagnostic Systems, Inc. Viral clearance process
NZ504021A (en) 1997-10-17 2003-04-29 Systemic Pulmonary Delivery Lt Method and apparatus for delivering aerosolized medication having air discharged through air tube directly into plume of aerosolized medication
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
US6302855B1 (en) 1998-05-20 2001-10-16 Novo Nordisk A/S Medical apparatus for use by a patient for medical self treatment of diabetes
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
BR0008758A (pt) 1999-01-15 2001-12-04 Genentech Inc Variantes de polipeptìdeos parentais com funçãoefetora alterada, polipeptìdeos, composição ácidonucleico isolado, vetor, célula hospedeira,método para produzir uma variante depolipeptìdeo, método para o tratamento de umadesordem em mamìferos e método para produziruma região fc variante
HK1042234A1 (zh) 1999-04-13 2002-08-09 Nektar Therapeutics 向肺部施加乾粉配方以治疗不育症
WO2000061178A1 (en) 1999-04-13 2000-10-19 Inhale Therapeutics Systems, Inc. Pulmonary administration of dry powder formulations for treating infertility
US6192891B1 (en) 1999-04-26 2001-02-27 Becton Dickinson And Company Integrated system including medication delivery pen, blood monitoring device, and lancer
GB9910975D0 (en) 1999-05-13 1999-07-14 Univ Strathclyde Rapid dehydration of proteins
US6277099B1 (en) 1999-08-06 2001-08-21 Becton, Dickinson And Company Medication delivery pen
PE20011227A1 (es) 2000-04-17 2002-01-07 Chiesi Farma Spa Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros
AU2001278716A1 (en) 2000-08-10 2002-02-25 Chugai Seiyaku Kabushiki Kaisha Method of inhibiting antibody-containing solution from coagulating or becoming turbid
AU2001271417B2 (en) 2000-08-30 2006-10-05 Johns Hopkins University Devices for intraocular drug delivery
PT1355919E (pt) 2000-12-12 2011-03-02 Medimmune Llc Moléculas com semivida longa, composições que as contêm e suas utilizações
JP4383168B2 (ja) 2001-09-12 2009-12-16 ベクトン・ディキンソン・アンド・カンパニー マイクロ針投与デバイスおよび薬物投与デバイス
JP4021194B2 (ja) 2001-12-28 2007-12-12 シャープ株式会社 薄膜トランジスタ装置の製造方法
WO2003074679A2 (en) 2002-03-01 2003-09-12 Xencor Antibody optimization
WO2003105757A2 (en) 2002-06-12 2003-12-24 Genencor International, Inc. Methods and compositions for milieu-dependent binding of a targeted agent to a target
EP1545611B1 (en) 2002-09-06 2016-11-09 Alexion Pharmaceuticals, Inc. Method of treatment of asthma using antibodies to complement component c5
US9415102B2 (en) * 2002-09-06 2016-08-16 Alexion Pharmaceuticals, Inc. High concentration formulations of anti-C5 antibodies
US20050271660A1 (en) 2002-09-06 2005-12-08 Alexion Pharmaceuticals, Inc. Nebulization of monoclonal antibodies for treating pulmonary diseases
US20040102469A1 (en) 2002-09-13 2004-05-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Method for reducing the mortality rate
GB0222023D0 (en) 2002-09-21 2002-10-30 Aventis Pharma Ltd Inhaler
CA2499816C (en) 2002-09-27 2013-07-30 Xencor, Inc. Optimized fc variants and methods for their generation
FR2849436B1 (fr) 2002-12-27 2007-01-05 Patrick Frayssinet Particules et ceramiques de phosphates de calcium pour transfection in vivo et in vitro
WO2004073551A2 (en) 2003-02-18 2004-09-02 Massachusetts Eye And Ear Infirmary Transscleral drug delivery device and related methods
DK1610820T4 (da) 2003-04-04 2013-11-04 Genentech Inc Høj-koncentration antistof- og proteinformuleringer
US20050054048A1 (en) 2003-07-29 2005-03-10 Luigi Grasso Antibodies and methods for generating genetically altered antibodies with enhanced effector function
US20070148170A1 (en) 2005-10-03 2007-06-28 Desjarlais John R Fc Variants With Optimized Fc Receptor Binding Properties
GB0324368D0 (en) 2003-10-17 2003-11-19 Univ Cambridge Tech Polypeptides including modified constant regions
WO2005077981A2 (en) 2003-12-22 2005-08-25 Xencor, Inc. Fc POLYPEPTIDES WITH NOVEL Fc LIGAND BINDING SITES
EP2053062A1 (en) 2004-03-24 2009-04-29 Xencor, Inc. Immunoglobin variants outside the Fc region
US8685435B2 (en) 2004-04-30 2014-04-01 Allergan, Inc. Extended release biodegradable ocular implants
US7919094B2 (en) 2004-06-10 2011-04-05 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
GB0416328D0 (en) 2004-07-21 2004-08-25 Univ Cardiff Use of dry powder compositions for pulmonary delivery
US20060074225A1 (en) 2004-09-14 2006-04-06 Xencor, Inc. Monomeric immunoglobulin Fc domains
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
BRPI0517837A (pt) 2004-11-12 2008-10-21 Xencor Inc variantes fc com ligação alterada a fcrn
US8802820B2 (en) 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
WO2006094234A1 (en) 2005-03-03 2006-09-08 Xencor, Inc. Methods for the design of libraries of protein variants
WO2006105338A2 (en) 2005-03-31 2006-10-05 Xencor, Inc. Fc VARIANTS WITH OPTIMIZED PROPERTIES
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
WO2007076062A2 (en) 2005-12-21 2007-07-05 Wyeth Protein formulations with reduced viscosity and uses thereof
US7807378B2 (en) * 2005-12-29 2010-10-05 Industrial Technology Research Institute (Itri) Method of diagnosing myasthenia gravis and kits therefor
EP1988882B1 (en) 2006-03-02 2014-12-17 Alexion Pharmaceuticals, Inc. Prolongation of survival of an allograft by inhibiting complement activity
DK2359834T5 (en) 2006-03-15 2017-02-06 Alexion Pharma Inc Treatment of paroxysmal nocturnal hemoglobinuria patients with a complement inhibitor
DK2006381T3 (en) 2006-03-31 2016-02-22 Chugai Pharmaceutical Co Ltd PROCEDURE FOR REGULATING ANTIBODIES BLOOD PHARMACOKINETICS
US8037880B2 (en) 2006-04-07 2011-10-18 The University Of Western Ontario Dry powder inhaler
US20100034194A1 (en) 2006-10-11 2010-02-11 Siemens Communications Inc. Eliminating unreachable subscribers in voice-over-ip networks
WO2008048545A2 (en) 2006-10-16 2008-04-24 Medimmune, Llc. Molecules with reduced half-lives, compositions and uses thereof
WO2008092117A2 (en) 2007-01-25 2008-07-31 Xencor, Inc. Immunoglobulins with modifications in the fcr binding region
AU2008266051B2 (en) 2007-06-14 2014-07-31 Biogen Ma Inc. Antibody formulations
CN101848733A (zh) 2007-07-13 2010-09-29 艾博特生物技术有限公司 用于肺部给予TNFα抑制剂的方法和组合物
DK2202245T3 (en) 2007-09-26 2016-11-21 Chugai Pharmaceutical Co Ltd A method of modifying an antibody isoelectric point VIA amino acid substitution in CDR
ES2742268T3 (es) 2007-12-26 2020-02-13 Xencor Inc Variantes de Fc con unión alterada a FcRn
PT2708559T (pt) 2008-04-11 2018-05-16 Chugai Pharmaceutical Co Ltd Molécula de ligação ao antigénio capaz de se ligar repetidamente a duas ou mais moléculas de antigénio
WO2010015608A1 (en) 2008-08-05 2010-02-11 Novartis Ag Compositions and methods for antibodies targeting complement protein c5
CA2739429C (en) 2008-10-14 2020-12-22 Lisa A. Damico Immunoglobulin variants and uses thereof
AU2015227544B2 (en) 2008-11-10 2017-05-25 Alexion Pharmaceuticals, Inc. Methods and compositions for treating complement-associated disorders
US20120282654A1 (en) 2009-04-29 2012-11-08 Schering Corporation Antibody purification
NZ597259A (en) 2009-06-23 2014-04-30 Alexion Pharma Inc Bispecific antibodies that bind to complement proteins
WO2011104381A2 (en) 2010-02-26 2011-09-01 Novo Nordisk A/S Stable antibody containing compositions
CN105218674A (zh) 2010-03-11 2016-01-06 瑞纳神经科学公司 呈pH依赖性抗原结合的抗体
TWI667346B (zh) 2010-03-30 2019-08-01 中外製藥股份有限公司 促進抗原消失之具有經修飾的FcRn親和力之抗體
CA2798120A1 (en) 2010-04-30 2011-11-03 Paul P. Tamburini Antibodies having reduced immunogenicity in a human
KR101800913B1 (ko) 2010-04-30 2017-12-20 알렉시온 파마슈티칼스, 인코포레이티드 항-c5a 항체들과 이 항체들을 이용하는 방법
MX365235B (es) 2010-11-30 2019-05-28 Chugai Pharmaceutical Co Ltd Molécula de unión a antígeno capaz de unir repetidamente a la pluralidad de moléculas de antígeno.
TWI803876B (zh) 2011-03-28 2023-06-01 法商賽諾菲公司 具有交叉結合區定向之雙重可變區類抗體結合蛋白
DK2698431T3 (da) 2011-03-30 2020-11-30 Chugai Pharmaceutical Co Ltd Opretholdelse af antigen-bindende molekyler i blodplasma og fremgangsmåde til modifikation af immunogenicitet
JP2014520148A (ja) 2011-06-20 2014-08-21 セントルイス ユニバーシティ 治療のための神経筋接合部への標的化
TW201326209A (zh) 2011-09-30 2013-07-01 Chugai Pharmaceutical Co Ltd 具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子
EP2762493B1 (en) 2011-09-30 2021-06-09 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule promoting disappearance of antigens having plurality of biological activities
ES2746103T3 (es) 2012-04-30 2020-03-04 Medimmune Llc Moléculas con función efectora reducida y semividas prolongadas, composiciones y usos de las mismas
EP2727602A1 (en) 2012-10-31 2014-05-07 Takeda GmbH Method for preparation of a high concentration liquid formulation of an antibody
PL2970974T3 (pl) 2013-03-14 2018-01-31 Alnylam Pharmaceuticals Inc Kompozycje komponentu C5 dopełniacza iRNA i sposoby ich zastosowania
AU2014306002B2 (en) 2013-08-07 2017-05-25 Alexion Pharmaceuticals, Inc. Atypical hemolytic uremic syndrome (aHUS) biomarker proteins
WO2016100190A1 (en) 2014-12-16 2016-06-23 Novartis Ag Low-water content acrylate-acrylamide copolymers for ophthalmic devices
HUE056489T2 (hu) 2014-12-19 2022-02-28 Chugai Pharmaceutical Co Ltd Anti-C5 antitestek és alkalmazási eljárások
EP3236772A4 (en) 2014-12-22 2018-10-17 Alexion Pharmaceuticals, Inc. Methods of purifying recombinant proteins
US20190135903A1 (en) 2015-03-31 2019-05-09 Alexion Pharmaceuticals, Inc. Identifying and treating subpopulations of paroxysmal nocturnal hemoglobinuria (pnh) patients
US20180311299A1 (en) 2015-05-01 2018-11-01 Alexion Pharmaceuticals, Inc. Efficacy of an anti-c5 antibody in the prevention of antibody mediated rejection in sensitized recipients of a kidney transplant
US20180142010A1 (en) 2015-06-26 2018-05-24 Alexion Pharmaceuticals, Inc. Method for treating a patient in compliance with vaccination with eculizumab or an eculizumab variant
JP2018528218A (ja) 2015-09-11 2018-09-27 アンドリアン、ブルース 組換えグリコシル化エクリズマブおよびエクリズマブ変異体
AU2016329034B2 (en) 2015-09-22 2019-05-23 Pfizer Inc. Method of preparing a therapeutic protein formulation and antibody formulation produced by such a method
ES2986888T3 (es) 2015-10-30 2024-11-13 Alexion Pharma Inc Un método para inhibir las exacerbaciones de la vasculopatía del aloinjerto mediada por células T
US20190023775A1 (en) 2016-01-11 2019-01-24 Alexion Pharmaceuticals, Inc. Dosage and administration of anti-c5 antibodies for treatment
JP2019517473A (ja) 2016-05-27 2019-06-24 アレクシオン ファーマシューティカルズ インコーポレイテッドＡｌｅｘｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 難治性全身型重症筋無力症の処置のための方法
MY191668A (en) 2016-06-14 2022-07-06 Regeneron Pharma Anti-c5 antibodies and uses thereof
WO2018044858A2 (en) * 2016-08-29 2018-03-08 The Cleveland Clinic Foundation C5 immunization for autologous anti-c5 antibody production
US20190276524A1 (en) 2016-10-12 2019-09-12 Alexion Pharmaceuticals, Inc. Efficacy of an anti-c5 antibody in the prevention of antibody mediated rejection in sensitized recipients of a kidney transplant
EP3554543A4 (en) 2016-12-16 2020-09-02 Samsung Bioepis Co., Ltd. STABLE Aqueous ANTI-C5 ANTIBODY COMPOSITION
CN110167961A (zh) 2017-01-31 2019-08-23 中外制药株式会社 用于治疗或预防c5相关疾病的药物组合物和治疗或预防c5相关疾病的方法
ES2965486T3 (es) 2017-07-27 2024-04-15 Alexion Pharma Inc Formulaciones de anticuerpos anti-C5 de alta concentración
KR20200070355A (ko) 2017-10-26 2020-06-17 알렉시온 파마슈티칼스, 인코포레이티드 발작성 야간 혈색소뇨 (pnh) 및 비정형 용혈성 요독 증후군 (ahus)의 치료를 위한 항-c5 항체의 투여량 및 투여
TW201938184A (zh) 2017-12-04 2019-10-01 美商Ｒａ製藥公司 補體活性之調節劑
ES2996257T3 (en) 2018-05-31 2025-02-12 Alexion Pharma Inc Dosage and administration of anti-c5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (pnh) in pediatric patients
EP3802603A1 (en) 2018-06-04 2021-04-14 Alexion Pharmaceuticals, Inc. Dosage and administration of anti-c5 antibodies for treatment of atypical hemolytic uremic syndrome (ahus) in pediatric patients
WO2020006266A1 (en) 2018-06-28 2020-01-02 Alexion Pharmaceuticals, Inc. Methods of producing anti-c5 antibodies
US12240893B2 (en) 2018-10-30 2025-03-04 Alexion Pharmaceuticals, Inc. Subcutaneous dosage and administration of anti-C5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (PNH)
EP3914617B1 (en) 2019-01-25 2024-03-13 Alexion Pharmaceuticals, Inc. Dosage and administration of anti-c5 antibodies for treatment of atypical hemolytic uremic syndrome (ahus)
WO2020168079A1 (en) 2019-02-14 2020-08-20 Alexion Pharmaceuticals, Inc. Dosage and administration of anti-c5 antibodies for treatment of generalized myasthenia gravis
WO2021091937A1 (en) 2019-11-08 2021-05-14 Alexion Pharmaceuticals, Inc. High concentration anti-c5 antibody formulations
EP4295905A1 (en) 2020-07-09 2023-12-27 Alexion Pharmaceuticals, Inc. Dosage and administration of anti-c5 antibodies for treating paroxysmal nocturnal hemoglobinuria (pnh) in pediatric patients
CA3196434A1 (en) 2020-10-23 2022-04-28 Krista K. JOHNSON Methods of treating patients having complement disorders using anti-c5 antibodies
WO2023287991A1 (en) 2021-07-14 2023-01-19 Alexion Pharmaceuticals, Inc. Dosage and administration of anti-c5 antibodies for treatment of myasthenia gravis

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012508262A (ja) * 2008-11-10 2012-04-05 アレクシオン ファーマシューティカルズ， インコーポレイテッド 補体関連障害を処置するための方法および組成物
WO2015134894A1 (en) * 2014-03-07 2015-09-11 Alexion Pharmaceuticals, Inc. Anti-c5 antibodies having improved pharmacokinetics

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
MUSCLE AND NERVE, vol. 48, JPN6021012313, 2013, pages 76 - 84, ISSN: 0004863760 *
NATIONAL INSTITUTE OF HEALTH RESEARCH [ONLINE], JPN6021012310, March 2016 (2016-03-01), ISSN: 0004863758 *
日腎会誌, vol. 56, JPN6021012311, 2014, pages 1090 - 1096, ISSN: 0004863759 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022126773A (ja) * 2016-05-27 2022-08-30 アレクシオン ファーマシューティカルズ インコーポレイテッド 難治性全身型重症筋無力症の処置のための方法
US12459992B2 (en) 2016-05-27 2025-11-04 Alexion Pharmaceuticals, Inc. Methods for treatment of refractory generalized myasthenia gravis

Also Published As

Publication number Publication date
CA3024618A1 (en) 2017-11-30
JP2024156984A (ja) 2024-11-06
EP3463461A1 (en) 2019-04-10
KR20190012199A (ko) 2019-02-08
US20250154234A1 (en) 2025-05-15
WO2017205101A1 (en) 2017-11-30
US20210246196A1 (en) 2021-08-12
BR112018073945A2 (pt) 2019-02-26
US12459992B2 (en) 2025-11-04
EP3463461A4 (en) 2020-05-20
AU2017269839A1 (en) 2018-11-22
JP2022126773A (ja) 2022-08-30
RU2018141451A3 (enExample) 2020-09-21
CN109475630A (zh) 2019-03-15
EP3909609A1 (en) 2021-11-17
RU2018141451A (ru) 2020-06-29
US20170342139A1 (en) 2017-11-30
MX2018014560A (es) 2019-08-12

Similar Documents

Publication Publication Date Title
JP2024156984A (ja) 難治性全身型重症筋無力症の処置のための方法
US20250243264A1 (en) Dosage and administration of anti-c5 antibodies for treatment of generalized myasthenia gravis
JP2024069373A (ja) 視神経脊髄炎の処置のためのエクリズマブ
JP2025084932A (ja) 視神経脊髄炎スペクトラム障害の治療のための抗ｃ５抗体
US20220259305A1 (en) Methods for treatment of refractory generalized myasthenia gravis with eculizumab
WO2023215443A1 (en) Compositions and methods for the treatment of neuromyelitis optica spectrum disorder
US20250154232A1 (en) Dosage and administration of anti-c5 antibodies for treatment of myasthenia gravis
JP7789672B2 (ja) 視神経脊髄炎スペクトラム障害の治療のための抗ｃ５抗体
US20220002393A1 (en) Methods for treatment of refractory generalized myasthenia gravis in pediatric patients
JP2025518796A (ja) 重症筋無力症の治療のための融合ポリペプチドの投薬量及び投与
WO2025054498A1 (en) Methods of treating hidradenitis suppurativa
CN117500827A (zh) 用于治疗皮肌炎（dm）的抗c5抗体的剂量和施用
EA046524B1 (ru) Доза и введение антител к c5 для лечения генерализованной миастении гравис
WO2021263056A1 (en) Dosage and administration of anti-c5 antibodies for treatment of amyotrophic lateral sclerosis

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200406

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200406

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210406

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210705

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211001

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220222

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220622

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20220622

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20220622

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20220712

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20220722

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20220726

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20220902

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20220913

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240513